Organization (Industry)
Symphogen (Denmark)
ClinicalTrials.gov lists Symphogen (Denmark) as lead sponsor of 16 trials. It has 42 active development programs and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Symphogen (Denmark): 16 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (19)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Colorectal Neoplasms | 7 |
| Neoplasm Metastasis | 5 |
| Carcinoma, Squamous Cell | 3 |
| Head and Neck Neoplasms | 3 |
| Lymphoma | 3 |
Showing 5 of 19 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 1 |
| 2016 | 6 |
| 2014 | 1 |
| 2011 | 1 |
| 2010 | 1 |
| 2008 | 1 |
Recruitment duration, a model prediction: none of the 16 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (42)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Sym022 | Neoplasm Metastasis | Phase 1 | 3 |
| Sym023 | Neoplasm Metastasis | Phase 1 | 3 |
| Sym021 | Neoplasm Metastasis | Phase 1 | 3 |
| Sym022 | Lymphoma | Phase 1 | 2 |
| Sym023 | Lymphoma | Phase 1 | 2 |
Showing 5 of 42 active programs.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| "Capecitabine" | 1 |
| FLUOROURACIL | 1 |
| NIVOLUMAB | 1 |
| Irinotecan | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 11% hit target (n=9) | 38% on time (n=8) |
Journals published in (6)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Blood | 1 |
| Cancer chemotherapy and pharmacology | 1 |
| Cancer discovery | 1 |
| Investigational new drugs | 1 |
| Journal of the National Cancer Institute | 1 |
Showing 5 of 6 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 24 | 3 | 2022-07-19 |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Swedish Orphan Biovitrum (Sweden) | Co sponsors trial with | 1 |
| Annick Desjardins | Co sponsors trial with | 1 |
Latest dated events (41)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2022-07-19 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2022-07-19 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2022-06-14 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2021-06-15 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2020-11-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 41 events.
Biomarker capability evidence (71)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD274 | Trial sponsor | Named in trial inclusion criteria |
| EGFR | Trial sponsor | Named in trial inclusion criteria |
| EGFR | Trial sponsor | Named in trial inclusion criteria |
| EGFR | Trial sponsor | Named in trial inclusion criteria |
| EGFR | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 71 evidence rows.
On Scientist.com
Symphogen (Denmark) is listed as a research supplier in the Scientist.com network.
Service areas
Symphogen develops recombinant antibody mixtures, a new class of antibody therapeutics for the treatment or prophylaxis of serious human diseases.
- Website
- www.symphogen.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Symphogen on Scientist.com
For prices, more details, or to contact Symphogen, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.